Health resource utilization and drug treatment pattern in a cohort of patients with a first episode of gastroesophageal reflux disease

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 7, 1999, Pages 493-500

  Rodríguez, Luis Alberto García ^a   Ruigómez, Ana ^a   Wallander, Mari Ann ^b   Johansson, Saga ^b   Stalhammar, Nils Olov ^b  

^a Department of Pharmacoepidemiology   (Spain)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Acid suppressing drugs; Automated database; Cohort study; Gastroesophageal reflux; Health resources use; Treatment failure

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0343851563     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199912)8:7<493::AID-PDS463>3.0.CO;2-O     Document Type: Article

References (22)

1. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 24-29.
2. Fennerty MB, Castell D, Fendrick M, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Suggested disease management guidelines. Archives of Internal Medicine 1996; 156: 477-482.
3. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scan J Gastroenterology 1989; 24(Suppl. 156): 7-13.
4. Brunton LL. Agents for control of gastric acidity and treatment of peptic ulcer. In: Goodman and Gilman's The pharmacological basis of therapeutics, 9th edn. McGrawHill, New York, 1996; pp. 901-915.
5. Sontag SJ. Rolling review: gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics 1993; 7: 293-312.
6. Talley NJ. Dyspepsia and heartburn: a clinical challenge. Alimentary Pharmacology and Therapeutics 1997; 11(2): 1-8.
7. Hallerbäck B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994; 107: 1305-1311.
8. Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Müller-Lissner SA. Three year follow up of patients with gastroeosphageal reflux disease. Gut 1992; 33: 1016-1019.
9. Robinson M, Lanza F, Avner D, Haber M. Effective Maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1996; 124: 859-867.
10. McDougall NI, Johnston BT, Kee F, Collins JSA, McFarland RJ, Love AHG. Natural history of reflux oesophagistis: a 10 year follow-up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-486.
11. Schindlbeck NE, Klauser AG, Voderholzer WA, Müller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Archives of Internal Medicine 1995; 155: 1808-1812.
12. Pope CE. Acid-reflux disorders. New England Journal of Medicine 1994; 331(10): 656-660.
13. Crooks GW, Lichtenstein GR. Clinical implications of Barret's eosphagus. Archives of Internal Medicine 1996; 156: 174-180.
14. Carlsson R, Gamliche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Alimentary Pharmacology and Therapeutics 1977; 11: 473-482.
15. García Rodríguez LA, Perez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. British Journal of Clinical Pharmacology 1998; 45: 419-425.
16. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. British Medical Journal 1991; 302: 766-768.
17. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerised data resource in the United Kingdom. Pharmacoepidemiology and Drug Safety 1992; 1: 347-349.
18. Van Staa J-P, Abenhaim L. The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycemia and other conditions. Pharmacoepidemiology and Drug Safety 1994; 3: 15-21.
19. Piper DW, Carle DJ, Talley NJ, et al. Gastrointestinal and hepatic diseases. In: Avery's Drug Treatment, 4th edn. Speight TM and Holford HG (Eds.). Adis International, Auckland, 1997; pp. 933-943.
20. Segal R, Russell WL, Ben-Joseph R, Mansheim B. Cost of acid peptic disorders in a managed-care organization. Clinical Therapeutics 1996; 18(2): 319-333.
21. Smith P, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994; 107: 1312-1318.
22. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastrooesophageal reflux disease in general practice. Scandinavian Journal of Gastroenterology 1997; 32: 965-973.